A sensitive solid-phase-extraction and high-performance liquid chromatography (HPLC) method has been developed to investigate the pharmacokinetics and metabolism of the hypoxic-cell cytotoxic agent tirapazamine (1,2,4-benzotriazine-3-amine 1,4-di-N-oxide; WIN 59075, SR 4233), currently in phase I/II studies in the United Kingdom and United States. A sample extraction and concentration process was devised using strong cationexchange Bond Elut cartridges. Tirapazamine, the mono and zero-N-oxide metabolites (WIN 64012, WIN 60109) were isocratically resolved using a μBondapak phenyl HPLC column and measured using photodiode-array detection. The minimal quantifiable level (MQL) of tirapazamine was 40 ng/ml in mouse plasma and 20 ng/ml in human plasma. Recovery was consistently greater than 80% for all compounds over the concentration range of 20 ng/ml to 20 μg/ml. No significant decomposition was observed following up to three freeze/thaw cycles and storage at −70°C for 52 days. The assay was accurate and reproducible, with measured values lying within the limits of defined acceptance criteria. Additional studies to investigate the degree of plasma protein binding showed that tirapazamine did not bind extensively to plasma proteins (binding, 9.7%±0.1% and 18.7%±1.3% in mouse and human plasma, respectively). These small species differences in protein binding are unlikely to have any major impact on the extrapolation of pharmacokinetic data from mice to humans. The assay has now been successfully applied to investigate the pharmacokinetics and metabolism of tirapazamine in mice and patients as part of a pharmacokinetically guided dose-escalation strategy for phase I clinical trials.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Brodfuehrer J, Whitfield LR, Kowal C, Grove W, Bullen W, Waterhouse D, Natale R (1992) Pharmacologically guided dose escalation in phase-I trial of CI-980. Proc Am Assoc Cancer Res 33: 529
Brown JM (1993) SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67: 1163–1170
Collins JM, Zaharko DS, Dedrick RL, Chabner BA (1986) Potential roles for preclinical pharmacology in phase-I clinical trials. Cancer Treat Rep 1: 73–80
EORTC Pharmacokinetics and Metabolism Group (1987) Pharmacokinetically guided dose escalation in phase-I clinical trials. Eur J Clin Oncol 7: 1083–1087
Gianni L, Vigani L, Surbone A, Ballinari D, Casali P, Tarella C, Collins J, Bonadonna G (1990) Pharmacology and clinical toxicity of 4-iodo-4-deoxydoxorubicin: an example of successful application of pharmacolinetics to dose escalation in phase-I trials. J Natl Cancer Inst 6: 469–477
Graham MA, Kaye SB (1993) New approaches in preclinical and clinical pharmacokinetics. In: Workman P, Graham MA (eds) Pharmacokinetics and cancer chemotherapy. Cancer surveys, vol 17) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp 27–49
Graham MA, Workman P (1992) The impact of pharmacokinetically guided dose escalation strategies in phase-I clinical trials: critical evaluation and recommendations for future studies. Ann Oncol 3: 339–347
Graham MA, Robin HJ, Senan S, Rampling R, Kaye SB, Workman P (1993) Pharmacokinetically guided dose escalation strategy for the hypoxic cell cytotoxic agent tirapazamine (WIN 59075, SR 4233). Proc Am Assoc Cancer Res 34: 390
Riley RJ, Hemingway SA, Graham MA, Workman P (1993) Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075). Biochem Pharmacol 45: 1065–1077
Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layoff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA, Spector S (1992) Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 81: 309–312
Walton MI, Workman P (1988) High performance liquid chromatographic assay for the benzotriazine di-N-oxide (SR 4233) and its reduced metabolites in biological materials. J Chromatogr 430: 429–437
Walton MI, Workman P (1990) Enzymology of the reductive bioactivation of SR 4233: a novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochem Pharmacol 39: 1735–1742
Walton MI, Workman P (1993) Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; NSC 130181) in mice. J Pharmacol Exp Ther 265: 938–947
Walton MI, Wolf CR, Workman P (1992) The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem Pharmacol 44: 251–259
Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW (1986) SR 4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12: 1239–1242
This work was supported by grants from the Cancer Research Campaign and Sterling Winthrop Pharmaceuticals. H. R. was awarded a visiting Research Fellowship sponsored by the Brazilian Medical Oncology Society
About this article
Cite this article
Robin, H., Senan, S., Workman, P. et al. Development and validation of a sensitive solid-phase-extraction and high-performance liquid chromatography assay for the bioreductive agent tirapazamine and its major metabolites in mouse and human plasma for pharmacokinetically guided dose escalation. Cancer Chemother. Pharmacol. 36, 266–270 (1995). https://doi.org/10.1007/BF00685859
- Bioreductive agents
- Pharmacokinetically guided dose escalation